Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JS207 with or without JS004 or docetaxel in advanced non-small cell lung cancer after progression on platinum chemotherapy and immunotherapy
CTR20251292Phase 2Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JS207, tifcemalimab, docetaxel in non-small cell lung cancer (NSCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Aug 2025; status: terminated.
02
Drugs
JS207tifcemalimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20251292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251292.